Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (10201)	9/9/2009 8:24:15 AM
From: DewDiligence_on_SI	Read Replies (1) \| Respond to of 10345

>I have to take issue with the notion that risk increases with time.< Cumulative risk clearly increases with time, which is the point of the WSJ article.

To: Harold Engstrom who wrote (10201)	9/9/2009 8:46:21 AM
From: kenhott	Respond to of 10345

With not that much more time (two years), the risk/benefit of this drug will be figured out by the MS community because the numbers will continue to grow (treatments and PML) and out there for the experts to process. I believe the PML risk increases with increased use but it doesn't matter what I think because I am a nobody. I posted the article not for investors (Most in the stock ELN has already strong opinions about this topic) but for patients of the drug. Investing is one thing, being a patient is another thing. Info for the most part is a good thing.